Search Within

Benjamin Heath Durham

  1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (7)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. Early Drug Development Service (20)
  4. Executive Committee, Center for Hematologic Malignancies (20)
  5. GSK Faculty (20)
  6. Hematologic Malignancies, Division of (20)

More Groups

People
  1. David Hyman (20)
  2. Eli Diamond (20)
  3. Omar Abdel-Wahab (20)
  4. Raajit Rampal (11)
  5. Gary Ulaner (10)
  6. Mario Lacouture (9)

More People

Years
  1. 2020 (2)
  2. 2019 (4)
  3. 2018 (5)
  4. 2017 (4)
  5. 2016 (1)
  6. 2015 (3)

More Years

Publications
  1. Blood (6)
  2. Pediatric Blood and Cancer (3)
  3. Neuro-Oncology (2)
  4. Cancer Discovery (1)
  5. Haematologica (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. Nature Publishing Group (3)
  3. Wiley Periodicals, Inc (3)
  4. Oxford University Press (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neurologic and oncologic features of Erdheim-Chester disease: A 30-patient series
    Journal Article

    Bhatia, A.; Hatzoglou, V.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Yabe, M.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation
    Meeting Abstract

    Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
    Journal Article

    Durham, B. H.; Lopez Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S. X.; Pastore, A.; Yoshimi, A.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Novel activating mutations in CSF1R and additional kinases with therapeutic implications in histiocytic neoplasms
    Meeting Abstract

    Durham, B.; Picarsic, J.; Lopez-Rodrigo, E.; Hyman, D.; Diamond, E.; Abdel-Wahab, O.
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Novel activating mutations in CSF1R and additional kinases with therapeutic implications in histiocytic neoplasms
    Meeting Abstract

    Durham, B.; Picarsic, J.; Lopez-Rodrigo, E.; Hyman, D.; Diamond, E.; Abdel-Wahab, O.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Efficacy of MEK inhibition in patients with histiocytic neoplasms
    Journal Article

    Diamond, E. L.; Durham, B. H.; Ulaner, G. A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R. J.; Francis, J. H.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Activating mutations in CSF1R and additional receptor tyrosine kinases in sporadic and familial histiocytic neoplasms
    Meeting Abstract

    Durham, B. H.; Lopez-Rodrigo, E.; Abramson, D. H.; Picarsic, J.; Pastore, A.; Mandelker, D.; Walsh, M. F.; Arcila, M. E.; Ladanyi, M.; Solit, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Single-agent dabrafenib for intracranial BRAFV600E-mutated histiocytosis
    Meeting Abstract

    Bhatia, A.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B.; Hajdenberg, J.; Ganzel, C.; Diamond, E.
    Neurology (2018)

    Fulltext@MSK | Save
  • Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
    Journal Article

    Taylor, J.; Pavlick, D.; Yoshimi, A.; Marcelus, C.; Chung, S. S.; Hechtman, J. F.; Benayed, R.; Cocco, E.; Durham, B. H.; Bitner, L.; more...
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study
    Journal Article

    Diamond, E. L.; Subbiah, V.; Lockhart, A. C.; Blay, J. Y.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J.; Erinjeri, J. P.; Torrisi, J.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save